ClinicalTrials.Veeva

Menu

A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy

L

London North West Healthcare NHS Trust

Status

Not yet enrolling

Conditions

IBD

Treatments

Diagnostic Test: TXI

Study type

Interventional

Funder types

Other

Identifiers

NCT07271264
RD25/051

Details and patient eligibility

About

Texture and Colour Enhancement Imaging (TXI) improves texture, brightness, and colour in white-light endoscopy to highlight subtle tissue differences. Now available through the EVIS X1 system, early evidence suggests potential value in IBD. Studies show that TXI may help predict ulcerative colitis relapse and performs comparably to dye chromoendoscopy in detecting lesions, though no randomised data exist for dysplasia detection in IBD surveillance. We therefore propose a randomised paired study comparing TXI with high-definition white-light endoscopy for dysplasia detection in IBD surveillance.

Full description

Texture and colour enhancement imaging (TXI) is designed to enhance texture, brightness and colour in white light in order to clearly define subtle tissue differences. This has been shown to enhance subtle tissue differences (20). This technology has recently become available in routine clinical practice with introduction of the EVIS X1 system (Olympus). Some promising data about the use of TXI in IBD are emerging. In a prospective observational study, 146 UC patients in endoscopic remission were evaluated with WLE and TXI. Patients with accentuated redness and poor visibility of deep vessels at TXI had significantly lower UC relapse-free rates than patients with no redness or accentuated redness alone, suggesting a possible role of TXI in guiding treatment intensification (21). In a small study of 16 IBD patients undergoing surveillance colonoscopy, TXI missed no lesions detected by subsequent dye chromoendoscopy (22). There are no randomised data regarding the utility of TXI for detection of dysplasia in colonoscopy IBD surveillance. We propose to undertake a randomised paired design study of Texture and Colour Enhancement Imaging (TXI) versus high-definition white light endoscopy for dysplasia detection in IBD surveillance.

Enrollment

219 estimated patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients >16 with inflammatory bowel disease undergoing surveillance colonoscopy.
  • Patients with Crohn's (L2/L3 Montreal classification) with >50% colonic involvement OR
  • Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD.

Exclusion criteria

  • Disease duration <8 years unless a diagnosis of PSC
  • Incomplete colonoscopy
  • BBPS <6 or <2 in any segment
  • MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for >10cm segment (above the rectum)
  • Previous colorectal resection
  • Thrombocytopaenia (platelet count <50) or Coagulopathy precluding biopsy
  • Anticoagulation that has not been held appropriately prior to the procedure (must be held at least the morning of the procedure).
  • Pregnancy
  • Unable or unwilling to consent to study participation

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

219 participants in 2 patient groups

TXI
Active Comparator group
Description:
Participants allocated to the "TXI" group undergo withdrawal using Texture and Colour Enhancement Imaging
Treatment:
Diagnostic Test: TXI
White light
Other group
Description:
Participants allocated in the "White light " group receive withdrawal with White light
Treatment:
Diagnostic Test: TXI

Trial contacts and locations

0

Loading...

Central trial contact

Jonathan Landy, Consultant Gastroenterologist

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems